

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-18. (Cancelled)

19. (Previously Presented) A method of regulating the expression of a nucleic acid sequence encoding a polypeptide which is immunogenic in a mammal, wherein said mammal has already made an immune response to said polypeptide, said method comprising:

- (a) obtaining a cell comprising a vector comprising a drug-regulatable promoter operably linked to said nucleic acid sequence encoding said polypeptide;
- (b) introducing said cell into said mammal; and
- (c) increasing expression of said polypeptide as a result of altering the amount of regulatory drug to which said cell is exposed.

20. (Previously Presented) The method of claim 19, wherein said cell is a leukocyte.

21. (Previously Presented) The method of claim 19, wherein said cell is a B lymphocyte, T lymphocyte, monocyte, or macrophage.

22. (Previously Presented) The method of claim 19, wherein said immune response comprises circulating antibodies against said polypeptide.

23. (Previously Presented) The method of claim 19, wherein said drug-regulatable promoter is a tetracycline-regulatable promoter.

24. (Previously Presented) The method of claim 19, wherein said regulatory drug is tetracycline or a tetracycline analog.
25. (Previously Presented) The method of claim 19, wherein said increase in expression of said polypeptide occurs two or more days after said introducing step.
26. (Previously Presented) The method of claim 19, wherein said vector is a viral vector.